Unmatched Experience in Early Phase Hematology and Oncology
Discover unparalleled expertise in phase I hematology and oncology study reviews with WCG. As the foremost leader in ethical and scientific review services for oncology studies in the US, we have successfully conducted over 3,300 early phase
oncology study reviews.
Our extensive partnerships with the most robust list of institutions and sites in the industry ensures a comprehensive approach to your research. Experience the future of streamlined efficiency through our coordinated IRB & IBC review process, and the highest quality DMC reviews, designed to alleviate the burdens faced by sponsors and CROs.
When it comes to early phase oncology review, no other IRB or IBC rivals our commitment, knowledge, and exceptional capabilities. Trust WCG’s IRB & IBC solutions to navigate the complexities of phase I oncology studies with confidence.
Clinical Trial Market
The global oncology market is growing at a rapid pace:
The US is no exception – with
oncology trials rapidly progressing.
WCG’s Answer
WCG is the industry leader in ethical review across all clinical trial phases.
Oncology and Hematology are two of our primary areas of expertise.
In fact, WCG leads the market in reviewing phase I oncology trials.
WCG’s Reach and Experience
The Largest Site Network Available:
Oncology-dedicated site and institution partners
Phase I oncology studies reviewed historically
Of all oncology studies* utilized WCG Review Solutions
*2018-2023
IBC registered sites globally
IRB determinations delivered 39% faster than goal TATs**
**Q2 2023 Average IRB TATs
Combined Years of Board Member Experience
Your oncology trial depends on expert review. Trust the industry leader!
Don't trust your study to just anyone.
WCG's IRB experts are standing by to handle your study with the utmost urgency and care. Contact us today to find out the WCG difference!